Literature DB >> 26009242

Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis.

Oliver Flossmann1.   

Abstract

Patients with ANCA-associated vasculitis (AAV) have an increased risk of premature death and organ failure. Treatment strategies with immune-suppressive drugs need to balance disease control and prevention of relapse against the risk of side effects in particular infection and malignancy. The longer-term outcome of patients with AAV who participated in several randomised controlled trials has been published in recent years. The results of these and other newer studies will be the focus of this review.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26009242     DOI： 10.1016/j.lpm.2015.02.019

Source DB:  PubMed          Journal:  Presse Med        ISSN： 0755-4982            Impact factor:   1.228


  6 in total

1.  Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis.

Authors:  Andrea Hinojosa-Azaola; Ariadna Jiménez-González; Natasha Alcocer-Castillejos
Journal:  Rheumatol Int       Date:  2017-12-15       Impact factor: 2.631

2.  Long-term Clinical Course of Antineutrophil Cytoplasmic Antibody-associated Vasculitis Patients off Maintenance Therapy.

Authors:  Eric J Gapud; Rebecca Manno; Philip Seo; Mohamad Hanouneh; Duvuru Geetha
Journal:  Cureus       Date:  2018-03-26

3.  Understanding Long-term Remission Off Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Susan L Hogan; Patrick H Nachman; Caroline J Poulton; Yichun Hu; Lauren N Blazek; Meghan E Free; J Charles Jennette; Ronald J Falk
Journal:  Kidney Int Rep       Date:  2019-01-28

4.  Outcomes and compliance with standards of care in anti-neutrophil cytoplasmic antibody-associated vasculitis-insights from a large multiregion audit.

Authors:  Fiona A Pearce; Catherine McGrath; Ravinder Sandhu; Jon Packham; Richard A Watts; Benjamin Rhodes; Reem Al-Jayyousi; Lorraine Harper; Karen Obrenovic; Peter Lanyon
Journal:  Rheumatol Adv Pract       Date:  2018-07-31

Review 5.  Rapidly progressive glomerulonephritis in children.

Authors:  Khemchand N Moorani; Madiha Aziz; Farhana Amanullah
Journal:  Pak J Med Sci       Date:  2022-01       Impact factor: 1.088

6.  Prediction of subclinical left ventricular dysfunction by speckle-tracking echocardiography in patients with anti-neutrophil cytoplasmic antibody--associated vasculitis.

Authors:  Tuba Nur İzgi; Dilek Barutcu Ataş; Halil Ataş; Dursun Akaslan; Can Ilgın; Arzu Velioğlu; Hakkı Arıkan; Fatma Alıbaz-Öner; Haner Direskeneli; Serhan Tuğlular; Ebru Aşıcıoğlu
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.